Mid-Afternoon Market Update: Dow Surges Over 200 Points; Immunic Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday.
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows.
Mid-Day Market Update: U.S. Stocks Turn Positive; Nasdaq Jumps 150 Points
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining 150 points on Thursday.
Piper Sandler Maintains Overweight on Immunic, Lowers Price Target to $39
Piper Sandler analyst Yasmeen Rahimi maintains Immunic (NASDAQ:IMUX) with a Overweight and lowers the price target from $71 to $39.
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Immunic Reports Will Present Preclinical Data For Vidofludimus Calcium At Congress Of European Crohn’s, Colitis Organization
Top-Line Data of the CALDOSE-1 Trial Expected to be Available in June of 2022
NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a